Wnt-pathway activation during the early stage of neurodegeneration in FTDP-17 mice

Neurobiology of Aging

Volumn 30, Issue 1, 2009, Pages 14-21

  Wiedau Pazos, Martina ^a   Wong, Eugene ^a   Solomon, Esther ^a   Alarcon, Maricela ^a   Geschwind, Daniel H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dementia; Transgenic animal model; Wnt pathway

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LYMPHOID ENHANCER FACTOR 1; TAU PROTEIN; TRANSCRIPTION FACTOR 7; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CHROMOSOME 17; CONTROLLED STUDY; FRONTOTEMPORAL DEMENTIA; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

AGING; ANIMALS; BRAIN; DEMENTIA; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SPINAL CORD; WNT PROTEINS;

EID: 56049086599     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.05.015     Document Type: Article

References (28)

1. Aberle H., Bauer A., Stappert J., Kispert A., and Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16 13 (1997) 3797-3804
2. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., and Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 4 (2002) 153-165
3. Behrens J., Jerchow B.A., Wuertele M., Grimm J., Asbrand C., Wirtz R., Kuehl M., Wedlich D., and Birchmeier W. Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK-3β. Science 280 5363 (1998) 596-599
4. Biernat J., Mandelkow E.M., Schröter C., Lichtenberg-Kraag B., Steiner B., Berling B., Meyer H., Mercken M., Vandermeeren A., and Goedert M. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11 4 (1992) 1593-1597
5. Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A.J., Caruso A., Storto M., Gaviraghi G., Terstappen G.C., and Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 24 (2004) 6021-6027
6. Clevers H., and van de Wetering M. TCF/LEF factors earn their wings. Trends Genet. 13 (1997) 485-489
7. DasGupta R., and Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 126 20 (1999) 4557-4568
8. Engel T., Hernandez F., Avila J., and Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. 2. Neurobiol. Dis. 26 19 (2002) 5083-5090
9. Goedert M., Spillantini M.G., Cairns N.J., and Crowther R.A. Tau proteins of Alzheimer paired helocal filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8 (1997) 159-168
10. Gustke N., Steiner B., Mandelkow E.M., Biernat J., Meyer H.E., Goedert M., and Mandelkow E. The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett. 307 (1992) 199-205
11. Hernandez F., Borrell J., Guaza C., Avila J., and Lucas J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau-filaments. J. Neurochem. 83 (2002) 1529-1533
12. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., and Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34 4 (2002) 509-519
13. Jin N., Kovacs A.D., Sui Z., Dewhurst S., and Maggirwar S.B. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48 4 (2005) 576-583
14. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
15. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
16. Lee C.W., Lau K.F., Miller C.C., and Shaw P.C. Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. Neuroreport 14 2 (2003) 257-260
17. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaiu P., Van Slegtenhorst M., Gwinn-Hardy K., Murphy M.P., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 4 (2000) 402-405
18. Lovestone S., and Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78 (1997) 309-324
19. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20 (2001) 27-39
20. Mattson M.P. Neuronal death and GSK-3β: a tau-fetish?. Trends Neurosci. 24 5 (2001) 255-256
21. Moon R.T., Bowerman B., Boutros M., and Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 296 (2002) 1644-1646
22. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., and Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A 102 19 (2005) 6990-6995
23. Sahara N., Lewis J., De Ture M., McGowan E., Dickson D.W., Hutton M., and Yen S.H. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem. 83 6 (2002) 1498-1508
24. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
25. Sheskin D.J. The Handbook of Parametric and Nonparametric Statistical Procedures. 3rd ed. (2003), CRC Press, Boca Raton 719 pp
26. Spittaels K., Van Den Haut C., Van Dorpe, Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen L., Boon T., Van Lint J., Vandenheede J., Moechars D., Loos R., and Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275 (2000) 41340-41349
27. Wittmann C.W., Wszolek M.F., Shulman J.M., Salvaterra P.M., Lewis J., Hutton M., and Feany M.B. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293 5530 (2001) 711-714
28. Yost C.M., Torres M., Miller J.R., Huang E., Kimelman D., and Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin are regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10 (1996) 1443-1454